Neoadjuvant Degarelix With or Without Apalutamide (ARN-509) Followed by Radical Prostatectomy

PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 28, 2019

Primary Completion Date

July 1, 2021

Study Completion Date

July 1, 2024

Conditions

Prostate CancerNeoadjuvant TherapyAndrogen AntagonistsProstatectomy

Interventions

DRUG

ARN-509

240mg/day (4x60mg tablets, Oral administration: OS)

DRUG

Degarelix

1st injection: 120mg Subcutaneous administration (SC) x2, 2nd-3rd SC injection 80mg monthly

OTHER

Placebo

4 tablets, per OS

Trial Locations (1)

University Hospitals Leuven, Leuven

All Listed Sponsors

lead

Universitaire Ziekenhuizen KU Leuven

OTHER

NCT03080116 - Neoadjuvant Degarelix With or Without Apalutamide (ARN-509) Followed by Radical Prostatectomy | Biotech Hunter | Biotech Hunter